הנתון שעשוי לנבא את הצלחת הטיפול בסרטן

הערכה

A large study of nearly 4,900 metastatic prostate cancer patients found that those whose PSA levels dropped below 0.2 within nine months had a 54 percent lower risk of death. The researchers caution that the rate of decline alone is not always sufficient to gauge treatment success. This suggests that while early PSA suppression is a strong prognostic signal, clinicians will need to integrate it with other factors. The finding could reshape how treatment efficacy is measured in advanced prostate cancer.